DK2269631T4 - Farmaceutiske sammensætninger, omfattende botulinumneurotoksin, til anvendelse inden for medicin og kosmetik - Google Patents

Farmaceutiske sammensætninger, omfattende botulinumneurotoksin, til anvendelse inden for medicin og kosmetik Download PDF

Info

Publication number
DK2269631T4
DK2269631T4 DK10010686.3T DK10010686T DK2269631T4 DK 2269631 T4 DK2269631 T4 DK 2269631T4 DK 10010686 T DK10010686 T DK 10010686T DK 2269631 T4 DK2269631 T4 DK 2269631T4
Authority
DK
Denmark
Prior art keywords
cosmetics
medicine
pharmaceutical compositions
botulinum neurotoxin
neurotoxin
Prior art date
Application number
DK10010686.3T
Other languages
Danish (da)
English (en)
Other versions
DK2269631T3 (da
Inventor
Paul Webb
Mary White
Julie Partington
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32865775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2269631(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Application granted granted Critical
Publication of DK2269631T3 publication Critical patent/DK2269631T3/da
Publication of DK2269631T4 publication Critical patent/DK2269631T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
DK10010686.3T 2004-07-12 2005-07-06 Farmaceutiske sammensætninger, omfattende botulinumneurotoksin, til anvendelse inden for medicin og kosmetik DK2269631T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0415491A GB2416122A (en) 2004-07-12 2004-07-12 Botulinum neurotoxin composition
EP05757842.9A EP1817051B2 (en) 2004-07-12 2005-07-06 Pharmaceutical compositions comprising botulinum neurotoxin, a non ionic surfactant, sodium chloride and sucrose

Publications (2)

Publication Number Publication Date
DK2269631T3 DK2269631T3 (da) 2013-12-09
DK2269631T4 true DK2269631T4 (da) 2019-08-19

Family

ID=32865775

Family Applications (3)

Application Number Title Priority Date Filing Date
DK10010686.3T DK2269631T4 (da) 2004-07-12 2005-07-06 Farmaceutiske sammensætninger, omfattende botulinumneurotoksin, til anvendelse inden for medicin og kosmetik
DK15000178.2T DK2939688T3 (da) 2004-07-12 2005-07-06 Farmaceutiske sammensætninger omfattende botulinumneurotoksin
DK05757842.9T DK1817051T4 (da) 2004-07-12 2005-07-06 Farmaceutiske sammensætninger, der omfatter botulinum-neurotoksin, et ikke-ionisk overfladeaktivt stof, natriumchlorid og saccharose

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK15000178.2T DK2939688T3 (da) 2004-07-12 2005-07-06 Farmaceutiske sammensætninger omfattende botulinumneurotoksin
DK05757842.9T DK1817051T4 (da) 2004-07-12 2005-07-06 Farmaceutiske sammensætninger, der omfatter botulinum-neurotoksin, et ikke-ionisk overfladeaktivt stof, natriumchlorid og saccharose

Country Status (19)

Country Link
US (4) US9125804B2 (enExample)
EP (4) EP3446701B1 (enExample)
JP (2) JP5301830B2 (enExample)
CN (2) CN102327602B (enExample)
AR (2) AR049978A1 (enExample)
BR (1) BRPI0513327B8 (enExample)
CA (1) CA2572915C (enExample)
DK (3) DK2269631T4 (enExample)
ES (3) ES2537312T5 (enExample)
FI (1) FI1817051T4 (enExample)
GB (1) GB2416122A (enExample)
HU (2) HUE025434T2 (enExample)
IL (1) IL180380A (enExample)
MX (1) MX2007000409A (enExample)
PL (3) PL1817051T5 (enExample)
PT (3) PT1817051E (enExample)
RU (1) RU2407541C2 (enExample)
TR (1) TR201906275T4 (enExample)
WO (1) WO2006005910A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
SG150570A1 (en) 2004-03-03 2009-03-30 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
SG160357A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
AU2006346369B2 (en) 2005-07-18 2013-02-21 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
FR2889936B1 (fr) 2005-09-01 2007-12-21 Sod Conseils Rech Applic Methode pour quantifier une neurotoxine cholinergique dans un echantillon
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
AU2016204034B2 (en) * 2005-10-06 2017-12-21 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
MX2008006750A (es) 2005-12-01 2008-09-03 Univ Massachusetts Lowell Nanoemulsiones de botulinum.
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
WO2008140594A2 (en) 2006-12-01 2008-11-20 Anterios, Inc. Peptide nanoparticles and uses therefor
AU2007329579A1 (en) * 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
CN103961315A (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
JP5259710B2 (ja) 2007-07-10 2013-08-07 メディ‐トックス、インク． ボツリヌス毒素の安定性が改善された薬学的液状組成物
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
BRPI0914630A2 (pt) * 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
CN101386648B (zh) * 2008-09-25 2012-05-30 中国人民解放军军事医学科学院微生物流行病研究所 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途
EP2373294B1 (en) * 2008-12-10 2016-04-20 Allergan, Inc. Clostridial toxin pharmaceutical compositions
BRPI0923731B1 (pt) 2008-12-31 2024-02-06 Revance Therapeutics, Inc Composições para uso em um método não-terapêutico de administração de toxina botulínica, seus usos e método de preparação
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
BRPI1015938A2 (pt) * 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
CA2814054A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
ES2810098T3 (es) * 2011-03-31 2021-03-08 Medy Tox Inc Preparación liofilizada de toxina botulínica
WO2013049139A1 (en) * 2011-09-28 2013-04-04 Wisconsin Alumni Research Foundation Purification, characterization, and use of clostridium botulinum neurotoxin bont/a3
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
JP2015534814A (ja) * 2012-10-31 2015-12-07 イプセン バイオイノベーション リミテッド 組換えクロストリジウムボツリヌス神経毒
KR20160007496A (ko) 2013-03-15 2016-01-20 오프로 테라퓨틱스 인코퍼레이션 점액 점도 정상화를 위한 생성물 및 방법
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
RU2593344C2 (ru) * 2014-03-05 2016-08-10 Михаил Григорьевич Сойхер Способ лечения бруксизма
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
AR103243A1 (es) 2014-12-23 2017-04-26 Merz Pharma Gmbh & Co Kgaa Recipiente precargado con toxina botulínica
RU2722290C2 (ru) 2015-02-03 2020-05-28 Мерц Фарма Гмбх Унд Ко. Кгаа Контейнер, предварительно заполненный ботулиновым токсином
KR102794108B1 (ko) 2015-10-29 2025-04-11 레반스 테라퓨틱스, 아이엔씨. 주사용 보툴리눔 독소 제제 및 긴 지속기간의 치료적 또는 미용적 효과를 갖는 이를 이용한 방법
US10874626B2 (en) 2016-04-07 2020-12-29 Nevakar Inc. Formulation for use in a method of treatment of pain
SI3679946T1 (sl) * 2016-05-27 2022-04-29 Ipsen Biopharma Limited Tekoča nevrotoksinska formulacija, stabilizirana s triptofanom ali tirozinom
RU2651044C2 (ru) * 2016-08-22 2018-04-18 федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ им. ак. Е.Н. Мешалкина" Минздрава России) Способ лечения желудочковых нарушений ритма сердца (варианты)
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
TW202247855A (zh) 2016-09-13 2022-12-16 美商愛力根公司 非蛋白梭菌毒素組成物
CN117731591A (zh) 2016-11-21 2024-03-22 艾里奥治疗公司 大试剂的透皮递送
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
NZ756674A (en) 2017-02-16 2023-06-30 Sonnet Biotherapeutics Inc Albumin binding domain fusion proteins
US11547686B2 (en) 2017-10-03 2023-01-10 Nevakar Injectables Inc. Acetaminophen pregabalin combinations and methods of treating pain
US10918586B2 (en) * 2017-12-07 2021-02-16 Ps Therapy Ltd. Topical compositions and methods of use thereof
SG11202107565RA (en) 2019-02-21 2021-08-30 Merz Pharma Gmbh & Co Kgaa Novel uses of botulinum neurotoxin for the treatment of tremor
RU2728102C1 (ru) * 2019-12-19 2020-07-28 Александр Александрович Ильин Способ лечения гипертонуса латеральной крыловидной мышцы
KR102324855B1 (ko) * 2020-05-20 2021-11-11 오스템임플란트 주식회사 보툴리눔 독소를 포함하는 약제학적 액상 조성물
EP4265239A4 (en) * 2020-12-18 2024-11-06 ATGC Co., Ltd. PHARMACEUTICAL COMPOSITION FOR LONG-TERM STORAGE OF A LIQUID FORMULATION OF BOTULINUM TOXIN
CN119258202A (zh) * 2023-07-05 2025-01-07 重庆誉颜制药有限公司 一种肉毒毒素蛋白组合物及其应用
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457916A (en) 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
WO1994007510A1 (en) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US20030095927A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
EP1053014A4 (en) † 1998-01-26 2004-11-10 Univ Massachusetts BIOLOGICALLY ACTIVE HEMAGGLUTININE TYPE A i (STRIDIUM BOTULINUM) AND METHOD FOR ITS USE
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
IL149778A0 (en) † 1999-11-22 2002-11-10 Universal Preservation Technologies Inc Preservation of sensitive biological material
NZ520201A (en) † 2000-02-08 2004-04-30 Allergan Inc Botulinum toxin pharmaceutical compositions comprising a polysaccharide
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20020197278A1 (en) 2001-06-21 2002-12-26 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
WO2003101483A1 (en) * 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
RU2206337C1 (ru) * 2002-10-29 2003-06-20 Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" Лекарственный препарат для лечения мышечных дистоний и способ его получения
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
EP2813239B1 (en) * 2004-08-04 2017-03-22 Ipsen Biopharm Limited Pharmaceutical composition containing botulinum neurotoxin A2
WO2006013370A1 (en) 2004-08-04 2006-02-09 Ipsen Limited Pharmaceutical composition containing botulinum neurotoxin a2
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions

Also Published As

Publication number Publication date
US20080050352A1 (en) 2008-02-28
PT2269631E (pt) 2014-01-08
ES2537312T3 (es) 2015-06-05
JP5662379B2 (ja) 2015-01-28
DK2939688T3 (da) 2019-05-13
PL2269631T5 (pl) 2020-08-10
ES2725908T3 (es) 2019-09-30
WO2006005910A2 (en) 2006-01-19
US20170348226A1 (en) 2017-12-07
EP2939688B1 (en) 2019-02-20
CN1984675A (zh) 2007-06-20
HUE043301T2 (hu) 2019-08-28
JP2012211150A (ja) 2012-11-01
RU2007101307A (ru) 2008-08-20
BRPI0513327B1 (pt) 2020-09-29
IL180380A0 (en) 2007-06-03
EP2269631B1 (en) 2013-10-09
AR049978A1 (es) 2006-09-20
EP1817051A2 (en) 2007-08-15
ES2537312T5 (es) 2024-09-18
CA2572915C (en) 2015-01-20
AR108998A2 (es) 2018-10-17
US20150328293A1 (en) 2015-11-19
US11534394B2 (en) 2022-12-27
CA2572915A1 (en) 2006-01-19
EP2269631B2 (en) 2019-06-12
EP1817051B2 (en) 2024-04-10
BRPI0513327B8 (pt) 2021-05-25
US10561604B2 (en) 2020-02-18
EP1817051B1 (en) 2015-02-25
DK2269631T3 (da) 2013-12-09
PL2939688T3 (pl) 2019-12-31
ES2438780T3 (es) 2014-01-20
HUE025434T2 (en) 2016-05-30
US9757329B2 (en) 2017-09-12
GB0415491D0 (en) 2004-08-11
CN102327602A (zh) 2012-01-25
CN1984675B (zh) 2011-11-09
MX2007000409A (es) 2007-06-25
IL180380A (en) 2015-11-30
PL1817051T3 (pl) 2015-07-31
PL1817051T5 (pl) 2024-07-29
GB2416122A (en) 2006-01-18
HK1152863A1 (en) 2012-03-16
JP5301830B2 (ja) 2013-09-25
ES2438780T5 (es) 2019-12-23
EP3446701B1 (en) 2025-11-19
TR201906275T4 (tr) 2019-05-21
EP3446701A1 (en) 2019-02-27
US20200164050A1 (en) 2020-05-28
FI1817051T4 (fi) 2024-05-02
PT1817051E (pt) 2015-06-03
JP2008505961A (ja) 2008-02-28
PT2939688T (pt) 2019-05-28
DK1817051T4 (da) 2024-05-06
EP2269631A3 (en) 2012-04-11
CN102327602B (zh) 2017-07-07
DK1817051T3 (en) 2015-06-01
HK1102495A1 (en) 2007-11-23
PL2269631T3 (pl) 2014-02-28
EP2269631A2 (en) 2011-01-05
WO2006005910A3 (en) 2006-09-14
RU2407541C2 (ru) 2010-12-27
EP2939688A1 (en) 2015-11-04
BRPI0513327A (pt) 2008-05-06
US9125804B2 (en) 2015-09-08

Similar Documents

Publication Publication Date Title
DK2269631T4 (da) Farmaceutiske sammensætninger, omfattende botulinumneurotoksin, til anvendelse inden for medicin og kosmetik
IS8542A (is) Efni, lyfjasamsetningar og notkun á efnum til að framleiða lyf gegn efnaskiptaröskunum
BRPI0813897A2 (pt) Uso de uma substância, composição cosmética ou dermo-cosmética ou neutracêutica, composição farmacêutica, método de cuidado cosmético, e, seqüência de nucleotídeos.
NO340679B1 (no) Pyridazinonderivativer, farmasøytiske preparater omfattende slike og slike forbindelser og preparater for anvendelse i terapeutisk aktive substanser til behandling og forebygging av sykdommer
DK1490062T3 (da) Glukokortikoidmimetika, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger og anvendelser deraf
DK1962807T3 (da) Film-coatet og/eller granuleret calcium-indeholdende forbindelser og anvendelse deraf i farmaceutiske sammensætninger
NO20090305L (no) Cyklosporin formuleringer
NO20053987L (no) Flytende farmasoytiske palonosetronformuleringer
FR2961814B1 (fr) Nouveaux peptides activateurs de la sirtuine 6 et composition cosmetique ou pharmaceutiques les comprenant.
DK1781256T3 (da) Phospholipid-gel-sammensætning til lægemiddelafgivelse og fremgangsmåder til behandling af sygdomme ved hjælp af samme
ATE490967T1 (de) 18-methyl-19-nor-androst-4-en-17,17-spiroether (18-methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
DK1635791T3 (da) Farmaceutisk komposition omfattende atorvastatin og fremstillet uden granulering
DK2373310T3 (da) Hidtil ukendte 4-(heterocycloalkyl)benzen-1,3-diolforbindelser som tyrosinaseinhibitorer, fremgangsmåde til fremstilling heraf og anvendelse heraf i human medicin og endvidere i kosmetik
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
PL1776137T3 (pl) Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową
DK1831149T3 (da) Hidtil ukendte ligander, der modulerer rar-receptorer, og anvendelse deraf i human medicin og i kosmetik
DK4110292T3 (da) Flydende, farmaceutisk sammensætning omfattende ensifentrin og glycopyrrolat
WO2007129162A3 (en) Pharmaceutical preparations for transdermal use
GB0417367D0 (en) Pharmaceutical composition containing botulinum neurotoxin
GB0423952D0 (en) Pharmaceutical composition containing botulinum neurotoxin
NO20042890L (no) Farmasoytiske preparater og fremgangsmate for fremstilling derav
DK1617827T3 (da) Farmaceutisk sammensætning i form af en hydrogel til den transdermale administration af aktivstoffer
IL204739A0 (en) Pharmaceutical compositions containing the enzyme cyprosin, an aspartic peptidase from cynara cardunculus and its inclusion in antitumour formulations
DK1791872T3 (da) Biotinylerede hexadecasaccharider, farmaceutiske præparater og anvendelse heraf
GB0423953D0 (en) Pharmaceutical composition containing botulinum neurotoxin